Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and RAD001 in Advanced Clear Cell Renal Carcinoma
NCT00323739Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, everolimus in clear cell renal cell carcinoma (ccRCC), sponsored by SCRI Development Innovations. Started May 2006; status: completed.
02
Drugs
bevacizumabeverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00323739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323739.